Sonnet BioTherapeutics has received a patent from the European Patent Office (EPO) for its fully human albumin binding (FHAB) technology.
The patent, Albumin Binding Domain Fusion Proteins No EP3583125 B1, encompasses therapeutic fusion proteins that utilise FHAB for the targeting and retention of tumours, and offers extended pharmacokinetics.
Effective until February 2038, the latest patent is set to expand the company’s intellectual property coverage, comprising China, the European Union, Japan, New Zealand, Russia and the US.
The platform comprises a single, fully human construct of an FHAB antibody fragment with a high affinity to attach to human albumin, offering an "off-the-shelf lock and load" approach for quick therapeutic biologics development.
Sonnet BioTherapeutics founder and CEO Pankaj Mohan stated: “The granting of this EU patent represents another milestone that provides expanded global protection along with building our intellectual capital and differentiation from any existing or emerging competitive technologies that may leverage the beneficial characteristics of binding to human serum albumin.”
SON-1010, or IL-12-FHAB, the company’s lead programme, is currently in a Phase I/IIa study.
The programme is part of a master clinical trial and supply agreement and ancillary quality and safety agreement with Roche, in which it is being tested in conjunction with atezolizumab (Tecentriq) for platinum-resistant ovarian cancer (PROC).
In partnership with the Sarcoma Oncology Center, the company is also advancing SON-1210, an IL12-FHAB-IL15 fusion protein. An investigator-initiated and funded Phase I/IIa study is set to begin for treating pancreatic cancer.
In November 2024, the company announced the issuance of US Patent No. 12,134,635, covering its new drug candidates, SON-1411 and SON-1400, which are expected to enhance cancer treatment options.
